Evidence map›Paper›PMID 35979909›Full record

ArticleBioconjugate chemistry2022

A New Class of Tunable Acid-Sensitive Linkers for Native Drug Release Based on the Trityl Protecting Group.

Matt Timmers, Jimmy Weterings, Michiel van Geijn, Roel Bell, Peter E Lenting, Cristianne J F Rijcken, Tina Vermonden, Wim E Hennink, Rob M J Liskamp

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matt TimmersCristal Therapeutics, Maastricht 6229 EV, The Netherlands.ORCID 0000-0002-2176-7505
Jimmy WeteringsCristal Therapeutics, Maastricht 6229 EV, The Netherlands.
Michiel van GeijnCristal Therapeutics, Maastricht 6229 EV, The Netherlands.
Roel BellSymeres, Nijmegen 6546 BB, The Netherlands.
Peter E LentingSchool of Chemistry, University of Glasgow, Glasgow G12 8QQ, U.K.
Cristianne J F RijckenCristal Therapeutics, Maastricht 6229 EV, The Netherlands.
Tina VermondenDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID 0000-0002-6047-5900
Wim E HenninkDepartment of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht 3584 CG, The Netherlands.ORCID 0000-0002-5750-714X
Rob M J LiskampCristal Therapeutics, Maastricht 6229 EV, The Netherlands.ORCID 0000-0001-8897-8975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Core-cross-linked polymeric micelles (CCPMs) are a promising nanoparticle platform due to favorable properties such as their long circulation and tumor disposition exploiting the enhanced permeability and retention (EPR) effect. Sustained release of covalently linked drugs from the hydrophobic core of the CCPM can be achieved by a biodegradable linker that connects the drug and the core. This study investigates the suitability of trityl-based linkers for the design of acid-triggered native active pharmaceutical ingredient (API) release from CCPMs. Trityl linker derivatives with different substituent patterns were synthesized and conjugated to model API compounds such as DMXAA-amine, doxorubicin, and gemcitabine, and their release kinetics were studied. Hereafter, API release from CCPMs based on mPEG-b-pHPMAmLac block copolymers was investigated. Variation of the trityl substitution pattern showed tunability of the API release rate from the trityl-based linker with

Indexed as

DoxorubicinMicellesAminesDelayed-Action PreparationsDrug CarriersDrug LiberationHydrogen-Ion ConcentrationPolyethylene GlycolsPolymersAminesDelayed-Action PreparationsDoxorubicinDrug CarriersMicellesPolyethylene GlycolsPolymers

Identifiers

PMID35979909
PMCPMC9501768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.